# GALLANT 5 Tesaglitazar Versus Metformin

> **NCT00214591** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 580 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GALIDA

## Key facts

- **NCT ID:** NCT00214591
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 580 (—)
- **Why stopped:** The development program has been terminated
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00214591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00214591, "GALLANT 5 Tesaglitazar Versus Metformin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00214591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*